[ad_1]
NEW YORK, NY / ACCESSWIRE / March 20, 2021 / Levi & Korsinsky, LLP announces that class actions have been filed on behalf of shareholders of the following publicly traded companies. Shareholders interested in acting as the main plaintiff have until the time limits indicated to apply to the court. For more details on the cases, see the links provided. There is no cost or obligation for you.
BLU shareholders Click here: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=13890&wire=1
AZN shareholders Click here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13890&wire=1
VLDR shareholders Click here: https://www.zlk.com/pslra-1/velodyne-lidar-inc-loss-submission-form?prid=13890&wire=1
* ADDITIONAL INFORMATION BELOW *
BELLUS Health Inc. (NASDAQ: BLU)
BLU pursuit on behalf of: investors who bought from September 5, 2019 to July 5, 2020
Lead Applicant Deadline May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=13890&wire=1
According to the complaint filed, during the class period, BELLUS Health Inc. made materially false and / or misleading statements and / or failed to disclose that: while the “high selectivity” of BLU-5937 contributed to the drug causes little or no taste alteration in patients with chronic cough, this high selectivity also contributed to the drug being potentially less effective and therefore probably not able to meet the d criterion primary evaluation of the Company’s Phase 2 trial.
Astrazeneca Plc (NYSE: AZN)
AZN legal action on behalf of: investors who bought from May 21, 2020 to November 20, 2020
Lead Applicant Deadline March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13890&wire=1
According to the complaint filed, during the class period, Astrazeneca Plc made materially false and / or misleading statements and / or did not disclose that: (a) the initial clinical trials for the Company’s COVID-19 vaccine, AZD1222, suffered from a manufacturing error, resulting in a substantial number of trial participants receiving half of the designed dose; (b) the clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and significance of any conclusions that could be drawn from the clinical data on these patient populations disparate; (c) some participants in the AZD1222 clinical trial did not receive a second dose at the designated times, but instead received the second dose up to several weeks after the dose was scheduled to be administered according to the schedule. initial test design; d) AstraZeneca did not include a significant number of patients over 55 years of age in its AZD1222 clinical trials, although this patient population is particularly vulnerable to the effects of COVID-19 and therefore constitutes a high priority target market for the drug; (e) AstraZeneca’s clinical trials for AZD1222 had been hampered by widespread design flaws, execution errors and lack of adequate coordination and communication with regulatory authorities and the general public; f) Due to a) to e) above, the clinical trials with AZD1222 were not conducted in accordance with best industry practice and acceptable standards and the data and conclusions that could be drawn from the clinical trials were limited. utility; and g) as a result of (a) – (f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Velodyne Lidar, Inc. (NASDAQ: VLDR)
VLDR lawsuit on behalf of: investors who bought from November 9, 2020 to February 19, 2021
Lead Applicant Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/velodyne-lidar-inc-loss-submission-form?prid=13890&wire=1
According to the complaint filed, during the course period, Velodyne Lidar, Inc. made materially false and / or misleading statements and / or failed to disclose that: (1) some of the directors of Velodyne did not act with respect , honesty, integrity, and candor in their dealings with officers and directors of the company; (2) the company was investigating the above issues; and (3) as a result of the foregoing, the positive statements by the defendants regarding the business, operations and prospects of the company were substantially misleading and / or lacked reasonable basis.
You have until the lead applicant’s deadline to ask the court to appoint you as the lead applicant. Your ability to participate in any recovery does not require you to act as the principal applicant.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington DC The attorneys at the firm have extensive expertise and experience in representing investors in stock market litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Lawyer advertising. Past results do not guarantee similar results.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th floor
New York, NY 10006
[email protected]
Phone: (212) 363-7500
Fax: (212) 363-7171
https://www.zlk.com
SOURCE: Levi & Korsinsky, LLP
See the source version on accesswire.com:
https://www.accesswire.com/636676/CLASS-ACTION-UPDATE-for-BLU-AZN-and-VLDR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of- Shareholders
Source link
